Browse by category

Results from the Phase 3 TRIUMPH-4 clinical trial evaluating the safety and efficacy of the two highest investigational doses of retatrutide, revealed retatrutide lowered weight by up to an average of 28.7% (71.2 lbs) and reduced pain by up to an average of 4.5 points (75.8%) using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score. Retatrutide is an investigational once-weekly triple hormone receptor agonist. Retatrutide is a single molecul

Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...